1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Diabetic Neuropathic Pain - Pipeline Review, H1 2016

Diabetic Neuropathic Pain - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 100 pages

Diabetic Neuropathic Pain - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Diabetic Neuropathic Pain - Pipeline Review, H1 2016’, provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathic Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
- The report reviews pipeline therapeutics for Diabetic Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Diabetic Neuropathic Pain - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathic Pain Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathic Pain - Overview 10
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11
Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 14
Diabetic Neuropathic Pain - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Diabetic Neuropathic Pain - Products under Development by Companies 18
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 19
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 20
Astellas Pharma Inc. 20
BioDelivery Sciences International, Inc. 21
Boehringer Ingelheim GmbH 22
Daiichi Sankyo Company, Limited 23
Eli Lilly and Company 24
Glenmark Pharmaceuticals Ltd. 25
Hydra Biosciences, Inc. 26
Immune Pharmaceuticals Inc. 27
Laboratorios Del Dr. Esteve S.A. 28
Lohocla Research Corporation 29
Mertiva AB 30
Novaremed 31
PeriphaGen, Inc. 32
Pharmaleads 33
Prismic Pharmaceuticals, Inc. 34
Relmada Therapeutics, Inc. 35
Sphaera Pharma Pvt. Ltd. 36
Theravasc, Inc. 37
Diabetic Neuropathic Pain - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
(amitriptyline + ketamine hydrochloride) - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
(diclofenac sodium + triclocarban) - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
AS-1069562 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
ASP-3662 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
capsaicin - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
clonidine hydrochloride - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
duloxetine hydrochloride DR - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
E-52862 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
EC-5026 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
filgrastim - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
GERPOOI - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
GRC-17536 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
HC-030031 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Kindolor - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
mepivacaine hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
mirogabalin besylate - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
NG2-GAD - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
NRD-135SE1 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
palmidrol - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
PGN-305 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
PL-37 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Small Molecule to Agonize CB2 for Diabetic Neuropathic Pain - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
sodium nitrite SR - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
Diabetic Neuropathic Pain - Recent Pipeline Updates 80
Diabetic Neuropathic Pain - Dormant Projects 88
Diabetic Neuropathic Pain - Discontinued Products 91
Diabetic Neuropathic Pain - Product Development Milestones 92
Featured News and Press Releases 92
Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 92
Sep 28, 2015: Pharmaleads Announces the Opening of French Sites in Its International Phase IIa Clinical Study of PL37 92
Apr 22, 2015: Pharmaleads Announces the Inclusion of the First Patient in Phase IIa Study of Oral PL37 for Pain in Diabetic Neuropathy 93
Mar 30, 2015: BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 94
Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin 94
Dec 08, 2014: BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy 95
Aug 06, 2014: BioDelivery Sciences Provides Update on Ongoing Phase 3 Pivotal Trial for Clonidine Topical Gel for Painful Diabetic Neuropathy 96
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 96
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 97
Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Tables
Number of Products under Development for Diabetic Neuropathic Pain, H1 2016 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Diabetic Neuropathic Pain - Pipeline by Astellas Pharma Inc., H1 2016 20
Diabetic Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2016 21
Diabetic Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2016 22
Diabetic Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 23
Diabetic Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2016 24
Diabetic Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 25
Diabetic Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H1 2016 26
Diabetic Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H1 2016 27
Diabetic Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 28
Diabetic Neuropathic Pain - Pipeline by Lohocla Research Corporation, H1 2016 29
Diabetic Neuropathic Pain - Pipeline by Mertiva AB, H1 2016 30
Diabetic Neuropathic Pain - Pipeline by Novaremed, H1 2016 31
Diabetic Neuropathic Pain - Pipeline by PeriphaGen, Inc., H1 2016 32
Diabetic Neuropathic Pain - Pipeline by Pharmaleads , H1 2016 33
Diabetic Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H1 2016 34
Diabetic Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H1 2016 35
Diabetic Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 36
Diabetic Neuropathic Pain - Pipeline by Theravasc, Inc., H1 2016 37
Assessment by Monotherapy Products, H1 2016 38
Assessment by Combination Products, H1 2016 39
Number of Products by Stage and Target, H1 2016 41
Number of Products by Stage and Mechanism of Action, H1 2016 43
Number of Products by Stage and Route of Administration, H1 2016 45
Number of Products by Stage and Molecule Type, H1 2016 47
Diabetic Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2016 80
Diabetic Neuropathic Pain - Dormant Projects, H1 2016 88
Diabetic Neuropathic Pain - Dormant Projects (Contd..1), H1 2016 89
Diabetic Neuropathic Pain - Dormant Projects (Contd..2), H1 2016 90
Diabetic Neuropathic Pain - Discontinued Products, H1 2016 91

List of Figures
Number of Products under Development for Diabetic Neuropathic Pain, H1 2016 10
Number of Products under Development for Diabetic Neuropathic Pain - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 38
Assessment by Combination Products, H1 2016 39
Number of Products by Top 10 Targets, H1 2016 40
Number of Products by Stage and Top 10 Targets, H1 2016 40
Number of Products by Top 10 Mechanism of Actions, H1 2016 42
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 42
Number of Products by Routes of Administration, H1 2016 44
Number of Products by Stage and Routes of Administration, H1 2016 44
Number of Products by Molecule Types, H1 2016 46
Number of Products by Stage and Molecule Types, H1 2016 46

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Rheumatoid Arthritis in 17 Major Markets Rheumatoid arthritis (RA) is classified as an autoimmune disease and occurs when the immune ...

Epiomic Epidemiology Series: Lower Back Pain and Sciatica Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Lower Back Pain and Sciatica Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lower Back Pain and Sciatica in 9 Major Markets Low back pain (LBP) is defined as experiencing musculoskeletal pain, muscle tension, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.